News and Trends 17 Apr 2019 UK Biotech Uses Genetic Engineering to Control Crop Munching Caterpillars Moth caterpillars attacking crops are the latest target of the UK company Oxitec, which uses genetic engineering to suppress the populations of crop pests and disease-carrying mosquitoes. The caterpillars of the soybean looper moth Chrysodeixis includens eat crops such as soybean, tomato and cotton across North and South America, causing problems for farmers. The caterpillars […] April 17, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2019 Male-Pattern Baldness Could See First New Treatment in over 10 Years A skin cream developed by the Italian company Cassiopea has reduced male-pattern baldness for up to 12 months in a phase II trial. Androgenetic alopecia, commonly known as male-pattern baldness in men, is a very common condition where excess male hormones (androgens) in hair follicles stop hair growing on the scalp. There are only two […] April 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Apr 2019 First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […] April 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2019 Swiss Multi-Cancer Diagnostic Test Approved in Europe A cancer test developed by the Swiss company SOPHiA GENETICS has been approved for diagnosing multiple types of solid tumors by looking at genetic variations in 42 genes. SOPHiA GENETICS works in data-driven medicine, using huge amounts of genomic data to diagnose and personalize treatments to a patient. This new technology is being adopted by […] April 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2019 Needle-Free Vaccine for Bubonic Plague to be Developed in the UK The UK biotech Enesi Pharma has joined forces with researchers from the University of Oxford to develop a vaccine for the bubonic plague that is simple to use and doesn’t require needles. Caused by the bacteria Yersinia pestis, the bubonic plague is infamous for having killed over 50 million Europeans in the Middle Ages. While […] April 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type 2 diabetes in a phase III trial in Japan. Poxel’s lead candidate drug imeglimin has taken a step closer to entering the huge market for diabetes type 2 treatments. In a phase III trial in […] April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Apr 2019 AACR 2019: European Biotech Progresses in Fighting Cancer The American Association for Cancer Research (AACR) met up in Atlanta, USA, to showcase the newest advances in cancer treatment from around the world. Sit back as we give you a quick rundown of the most interesting presentations from European organizations working to improve the treatment of cancer. Clinical trials In the conference last […] April 8, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2019 Update: Two-Drug HIV Treatment Effective for up to Three Years Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […] April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2019 Joint Venture First to Offer Seamless Manufacturing of Microbiome Therapies Lonza, a Swiss pharma supplier, and Chr. Hansen, a Danish supplier of bacterial products, are teaming up to enter the promising microbiome space. Together, the two companies will invest €90M in the creation of the first company that will offer a full supply chain to produce treatments made of live bacteria. Their 50/50 joint venture […] April 3, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2019 UK Scientists Activate Stem Cells to Heal Corneal Injuries A group of researchers in the UK has developed a potential treatment for corneal injuries, such as those caused by chemical burns, by making surrounding tissue softer and letting stem cells regenerate damaged tissue. The cornea is a transparent tissue that is important for focusing light onto the retina and guarding entry into the eye. […] April 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2019 Spare Parts: Exploring the Science of Repairing the Human Body London’s Science Gallery has gathered scientists and artists to create an exhibition that lets visitors peek at a not-so-distant future where custom implants and organ regeneration become the norm. The field of regenerative medicine has taken huge strides forward in recent years. Today, there’s talk of stem cells, smart implants, and 3D-printed organs all over […] April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Apr 2019 Cambridge Fund Raises €175M to Supercharge Local Life Sciences Ecosystem The UK venture capital fund Cambridge Innovation Capital, backed by the University of Cambridge, has raised €175M (£150M) to spend on life science and technology companies in the Cambridge area. The money will support the 25 companies in the fund’s portfolio, including the biotech Bicycle Therapeutics, whose peptide-toxin molecules are in clinical trials for the […] April 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email